Preventing heart disease during cancer treatment
Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes
['FUNDING_R01'] · KAISER FOUNDATION RESEARCH INSTITUTE · NIH-11121829
This project looks at whether starting cholesterol and blood‑pressure medicines in adults with breast cancer who receive heart‑risking treatments can prevent heart damage and help them complete cancer therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | KAISER FOUNDATION RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (Oakland, UNITED STATES) |
| Trial ID | NIH-11121829 on ClinicalTrials.gov |
What this research studies
Researchers will link Kaiser Permanente medical records with the SEER cancer registry, financial assistance records, and Social Security data to build a dataset of over 17,000 breast cancer patients. They will compare patients who received preventive anti‑hypertensive or lipid‑lowering medicines to those who did not while undergoing cardiotoxic treatments like high‑dose anthracyclines or certain targeted therapies. The team will track heart events, interruptions in cancer therapy, long‑term survival, and healthcare use over time. Findings aim to show whether primary prevention with these medicines reduces cardiovascular complications and preserves cancer treatment delivery.
Who could benefit from this research
Good fit: Adults with breast cancer—particularly those starting high‑dose anthracyclines or other cardiotoxic regimens and receiving care within Kaiser Permanente—are the ideal candidates for inclusion.
Not a fit: People without breast cancer, those not treated with cardiotoxic cancer drugs, or patients who receive care outside Kaiser Permanente are unlikely to be included or to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could reduce treatment‑related heart problems and help more patients complete their planned cancer therapy with better long‑term outcomes.
How similar studies have performed: Clinical guidelines and some smaller trials support using blood‑pressure and cholesterol drugs in high‑risk patients, but large real‑world studies focused on cancer patients are still limited.
Where this research is happening
Oakland, UNITED STATES
- KAISER FOUNDATION RESEARCH INSTITUTE — Oakland, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAWATKAR, ANIKET A — KAISER FOUNDATION RESEARCH INSTITUTE
- Study coordinator: KAWATKAR, ANIKET A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease